All In Biotech

Drug Trial Radar · NCT01708603

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2

Last checked: Nov 20, 2026Latest source record: Jan 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,831 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,831

Actual

Start

Aug 2012

Primary completion

Sep 2014

Study completion Oct 2015

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Oct 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses

Conditions

  • Moderate to Severe Plaque Psoriasis

Interventions

  • 210 mg brodalumabDrug

    210 mg brodalumab administered SC

  • 140 mg brodalumabDrug

    140 mg brodalumab administered SC

  • ustekinumabDrug

    45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.

  • placeboDrug

    Placebo administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12Time frame: 12 weeks
  2. Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12Time frame: 12 weeks
  3. Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12Time frame: 12 Weeks

Locations

153 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Irvine, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Vista, California

  • Research Site

    Denver, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Aventura, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Newnan, Georgia

  • Research Site

    Snellville, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Skokie, Illinois

  • Research Site

    Carmel, Indiana

  • Research Site

    Plainfield, Indiana

  • Research Site

    South Bend, Indiana

  • Research Site

    Louisville, Kentucky

  • Research Site

    Lake Charles, Louisiana

  • Research Site

    Lake Charles, Louisiana

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Rockville, Maryland

  • Research Site

    Silver Spring, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    North Andover, Massachusetts

  • Research Site

    Ann Arbor, Michigan

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.